Chardan Capital Thinks ContraFect’s Stock is Going to Recover


Chardan Capital analyst Keay Nakae reiterated a Buy rating on ContraFect (CFRX) yesterday and set a price target of $1.50. The company’s shares closed yesterday at $0.40, close to its 52-week low of $0.36.

According to TipRanks.com, Nakae is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.9% and a 34.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Emergent Biosolutions.

The the analyst consensus on ContraFect is currently a Hold rating.

See today’s analyst top recommended stocks >>

Based on ContraFect’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $5.94 million. In comparison, last year the company had a GAAP net loss of $19.11 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts